Medical therapy for clinically non-functioning pituitary adenomas.

Area of Science:

• Endocrinology
• Neurosurgery
• Oncology

Background:

• Non-functioning pituitary adenomas (NFAs) are often diagnosed late due to a lack of clinical syndromes, leading to compression symptoms like hypopituitarism and visual field defects.
• Surgery is the primary treatment, but residual tumor tissue is common, necessitating further management to prevent regrowth.

Purpose of the Study:

• To review the current treatment strategies for NFAs, focusing on the role of medical therapies in managing residual tumors and associated symptoms.
• To evaluate the efficacy of somatostatin analogues (SSA) and dopamine agonists (DA) in treating NFAs.

Main Methods:

• Review of existing literature on NFA treatments.
• Analysis of the expression of somatostatin and dopamine receptors on NFA cell membranes.
• Assessment of the reported effects of SSA, DA, and combination therapies on tumor size and clinical symptoms.

Main Results:

• While surgery is standard, residual tumors are frequent. Radiotherapy is often used post-surgery.
• Somatostatin analogues (SSA) and dopamine agonists (DA) have shown some benefits for visual defects and minor tumor shrinkage in a subset of patients.
• Dopamine agonists (DA) appear more effective for tumor shrinkage than SSA; combination therapy shows promise but requires further investigation. Gonadotropin-releasing hormone analogues are not recommended.

Conclusions:

• Medical therapies, particularly DA and potentially combination SSA/DA treatments, offer a potential adjunctive or alternative approach for managing NFAs, especially residual tumors.
• Further randomized, placebo-controlled trials are essential to establish the definitive efficacy of SSA and DA in NFA treatment.
• Current evidence suggests abandoning the use of gonadotropin-releasing hormone analogues for NFAs.